San Francisco, California, July 21, 2017: A report by TMR Research, titled “Cardiometabolic Disease Market – Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2017–2025,” offers an immaculate understanding of the market. These aspects include market dynamics, vendor landscape, and detailed analysis of the segmentation based on treatments and geography. The report offers insights into the statistics pertaining to the cardiometabolic disease market at both global and regional levels during the forecast period between 2017 and 2025.
The changing lifestyles, growing obesity and overweight conditions, and genetic predisposition are leading to the increased number of cases of type 2 diabetes mellitus, which in turn results in the greater risk of cardiometabolic diseases. Therefore, the mounting cases of cardiometabolic disease market are stoking the growth of the market. Besides this, patients suffering from hypertension are also at a high risk of these diseases. Rapid urbanization and shift towards sedentary lifestyles are also providing a fillip to the global cardiometabolic disease market.
The incidence of these diseases is increasing among children due to the increasing consumption of fast and high-fat food and reduced exercise. Moreover, the growing investments in research and development of treatments for these diseases are allowing the global market to gain significant momentum.
On the basis of treatments, the report segments the global cardiometabolic disease market into Glucophage, diuretics, ACE inhibitors, and liposuctions. From the geographical standpoint, the market is divided into Europe, North America, Latin America, Asia Pacific, and the Middle East and Africa. North America will continue to account for a sizeable share in the global arena. The growth of the region can be attributed to the increasing shift towards sedentary lifestyles and unhealthy diets. Various studies indicate that close to one-third of the population in the U.S. are affected by the metabolic syndrome.
Asia Pacific is anticipated to emerge as a prominent destination for key players in the coming years. The expanding pool of patients suffering from metabolic syndrome is contributing to the growth of the region. Moreover, the improving healthcare infrastructure and soaring demand for sophisticated and advanced therapeutic treatments are also propelling the growth of the region.
Key players in the global cardiometabolic disease market are paying high attention to research and development activities in order to create advanced and sophisticated therapeutics, which will help them in enhancing their visibility in this market. Companies are also focusing towards collaborations and strategic partnerships in order to expand their portfolios. Some of the prominent companies operating in the global cardiometabolic disease market are Spherix Incorporated, Cardax Pharmaceuticals Inc., Torrent Pharmaceutical Ltd., VivaCell Biotechnology Espana S.L., Abeille Pharmaceuticals Inc., and Indus Biotech Private Limited.